Medolife Rx Announces Adjustments to Management and Advancements to AELIA’s Internet marketing Endeavours

BURBANK, CA, Feb. 07, 2022 (World NEWSWIRE) — via NewMediaWire — Medolife Rx, Inc. (“Medolife”), a international built-in biopharmaceutical company with R&D, manufacturing, and shopper product distribution, which is a bulk owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced these days that the Corporation is in development of revamping their on the internet advertising platform, starting off with a change in the marketing and advertising and manufacturer growth for their AELIA manufacturer wellness products and solutions that use the company’s polarized elements. Medolife thinks these adjustments will carry increased product or service awareness and improved on the internet existence.

The Company’s manager of advertising and brand development, Maggie Dumais, has stepped down from their placement underneath mutual settlement with the Corporation. In buy to aid the Company’s eyesight of a new advertising and marketing system, Medolife is finalizing an settlement with a new director of promoting and brand name enhancement, whose identify will be declared at a later date.

“We are enthusiastic with the new path that the Company is using with its AELIA products and solutions and anticipate a optimistic result,” suggests Medolife CEO Dr. Mikaelian. “The Company’s values, goals and programs will be introduced in a way that displays our mission to promote overall health and properly-getting with our growing line of solutions.”

The Organization also employed a new workforce to oversee the overhaul of AELIA’s sites, product listings and social media presence. The Business hopes that, with the enable of these knowledgeable pros, their on line platforms will see an enhance in sale conversions and purchaser feed-back.

Medolife many thanks its shareholders and clients for believing in them. The Firm will have far more positive information coming out soon.

About Medolife Rx

Medolife Rx, Inc. is a worldwide biotechnology organization with functions in clinical investigate, production, and purchaser items. Medolife Rx was developed via the merger of Medolife, a private enterprise established by Dr. Arthur Mikaelian, who pioneered the unlaying polarization technological know-how, and Quanta, Inc., a immediate-to-buyer wellness merchandise portfolio firm. The Company’s lead medical growth plans consist of Escozine®, a proprietary formulation consisting of little molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technological innovation and is currently being researched as a treatment method of several indications, like COVID-19 and most cancers. The Company intends to go after merchandise registration and drug acceptance in many nations.

Through its subsidiary AELIA, Medolife manufactures and distributes buyer wellness products in shopper locations this sort of as suffering reduction, natural beauty, and normal wellness. AELIA goods are made employing Dr. Mikaelian’s polarization know-how, which applies advancements in quantum biology to increase the efficiency of energetic ingredients. Eventually, Quanta’s mission is to produce far better, much more efficient substances to elevate merchandise efficacy, reduce waste, and facilitate healthier, additional sustainable consumption.

Past its individual clinical and customer programs, the polarization engineering utilised by Medolife and its subsidiaries has quite a few prospective apps. From potentiating bio-ingredients, to developing additional-successful carbon-trapping plants, to transformative anti-aging solutions, Medolife could have the prospect to upend how commercial and pharmaceutical goods are designed and raise their rewards, while lowering their chemical focus.

Forward-Searching Statements

Protected Harbor Statement below the U.S. Private Securities Litigation Reform Act of 1995: This release has statements that are ahead-looking in nature which express the beliefs and anticipations of administration including statements pertaining to the Firm’s anticipated benefits of operations or liquidity statements regarding projections, predictions, anticipations, estimates or forecasts as to our business enterprise, money and operational results and long term financial performance and statements of management’s ambitions and goals and other related expressions about issues that are not historic details. In some scenarios, you can determine forward-searching statements by terminology these as “foresee,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “hope,” “we consider,” “we intend,” “could,” “will,” “must,” “could,” and related expressions. These types of statements are based mostly on recent plans, estimates and expectations and entail a range of known and unfamiliar threats, uncertainties and other aspects that could induce the Company’s future outcomes, overall performance or achievements to differ considerably from the outcomes, functionality or achievements expressed or implied by this kind of forward-seeking statements. These elements and extra information are talked over in the Firm’s filings with the Securities and Exchange Fee and statements in this release should be evaluated in gentle of these important aspects. Even though we feel that these statements are centered upon reasonable assumptions, we can not guarantee potential outcomes. Ahead-searching statements talk only as of the day on which they are manufactured, and the Corporation undertakes no obligation to update publicly or revise any ahead-looking statement, irrespective of whether as a consequence of new facts, foreseeable future developments or normally.

Contacts:

[email protected]

818-659-8052